Nivolumab With DA-REPOCH Chemotherapy Regimen in Treating Patients With Aggressive B-Cell Non-Hodgkin's Lymphoma

Inclusion Criteria: * Be willing and able to provide written informed consent/assent for the trial. * Measurable disease (defined as \>= 1.5 cm in diameter) or at least one PET avid area of disease. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Absolute neutrophil count (ANC) \>= 1,000 /mcL (within 16 days of treatment initiation). * Platelets \>= 75,000 / mcL in the absence of transfusion support within 7 days of determining eligibility (within 16 days of treatment initiation). * Hemoglobin \>= 8 g/dL (within 16 days of treatment initiation). * Serum creatinine =\< 1.5 X upper limit of normal (ULN) OR measured or calculated creatinine clearance \>= 40 mL/min creatinine clearance (glomerular filtration rate \[GFR\] can also be used in place of creatinine or creatinine clearance \[CrCl\]) (within 16 days of treatment initiation). * Creatinine clearance should be calculated per institutional standard. * Serum total bilirubin =\< 1.5 X ULN OR except subjects with Gilbert syndrome, who can have total bilirubin \< 3.0 mg/dL (within 16 days of treatment initiation). * Aspartate aminotransferase (AST) (serum glutamic oxaloacetic transaminase \[SGOT\]) and alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase \[SGPT\]) =\< 3.0 X ULN (within 16 days of treatment initiation). * Female subject of childbearing potential should have a negative serum pregnancy at screening. * Female subjects of childbearing potential should be willing to use 2…